Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Research results from Radboud University update knowledge of bladder cancer
October 7th, 2008
In this recently published article, scientists in Netherlands conducted a study "To describe clinical needs in non-muscle invasive bladder cancer (NMIBC) and review the potential of apaziquone in this respect. Epidemiology and clinical practice in NMIBC, as well as new drugs and strategies are reviewed." "Bladder cancer is a heterogeneous and frequent disease. Clinical risk factors help in determining additional therapy after initial resection. However, current treatments have clear limitations with regard to efficacy and/or. toxicity. New drugs and strategies have been tested recently and are in (pre)clinical use. Intravesical apaziquone (EOquin (TM)) is a new drug....
Source: Cancer Weekly (2008-10-07)
|
